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To compare the potential of a gadoxetate disodium enhanced navigator-triggered 3D T1
magnetic-resonance cholangiography (MRC) sequence with a specific inversion recovery
prepulse to T2-weighted MRCP for assessment of the hepatobiliary system.
Materials and methods
30 patients (12 male, 18 female) prospectively underwent conventional navigator-triggered
3D turbo spin-echo T2-weighted MRCP and 3D T1 MRC with a specific inversion pulse to
minimise signal from the liver 30 minutes after administration of gadoxetate disodium on a
1.5 T MRI system. For qualitative evaluation, biliary duct depiction was assessed segmen-
tally following a 5-point Likert scale. Visualisation of hilar structures as well as image quality
was recorded. Additionally, the extrahepatic bile ducts were assessed quantitatively by cal-
culation of signal-to-noise ratios (SNR).
Results
The advantages of T1 3D MRC include reduced affection of image quality by bowel move-
ment and robust depiction of the relative position of the extrahepatic bile ducts in relation to
the portal vein and the duodenum compared to T2 MRCP. However, overall T1 3D MRC did
not significantly (p > 0.05) improve the biliary duct depiction compared to T2 MRCP in all
segments: Common bile duct 4.1 vs. 4.4, right hepatic duct 3.6 vs. 4.2, left hepatic duct 3.5
vs. 4.1. Image quality did not differ significantly (p > 0.05) between both sequences (3.6 vs.
3.5). SNR measurements for the hepatobiliary system did not differ significantly (p > 0.05)
between navigator-triggered T1 3D MRC and T2 MRCP.
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Conclusions
This preliminary study demonstrates that T1 3D MRC of a specific inversion recovery pre-
pulse has potential to complement T2 MRCP, especially for the evaluation of liver structures
close to the hilum in the diagnostic work-up of the biliary system in patients receiving gadox-
etate disodium.
Introduction
Anatomical evaluation of the biliary system is of high importance in patients with biliary dis-
eases as well as with intrahepatic or hilar tumours of different aetiologies in the preoperative
setting. Magnetic resonance cholangiopancreaticography (MRCP) has proven its utility in a
variety of biliary and pancreatic diseases, including choledocholithiasis, congenital anatomic
variants, chronic pancreatitis, post-cholecystectomy disorders, and neoplastic duct obstruc-
tion. As a high level of diagnostic confidence can be achieved using MRCP at different scanner
systems and a different field strengths, this sequence type has contributed to the reduction of
the frequency of invasive procedures, especially of direct endoscopic cholangiopancreaticogra-
phy [1–5].
T2-weighted MRCP with a high spatial resolution is a clinically established MR sequence
for visualisation of the pancreatobiliary anatomy. However, a relatively long echo time (TE) is
used to acquire this sequence. Therefore, MRCP is susceptible to potential artefacts and pit-
falls, e.g. respiratory motion artefacts, susceptibility artefacts by gastric-duodenal gas and arte-
facts from surrounding fluid-containing structures, especially the small intestine. Additionally,
pulsatility from adjacent vascular structures may cause artefacts interfering with luminal con-
tours of the biliary tract thereby causing pseudo-obstruction [6, 7].
Gadoxetate disodium is excreted by hepatocytes into the biliary system with a peak after 10
to 20 minutes [8]. A substantial amount (up to 50%) of gadoxetate disodium is excreted via the
biliary system [9]. As a result, the bile and the hepatobiliary system can directly be visualised
on T1-weighted sequences, due to the resulting strong T1 shortening effect of the excreted
contrast agent [10, 11].
In this study we used in respiratory navigator-gated T1 inversion recovery sequence specifi-
cally optimized to visualise the hepatobiliary system with a high contrast. The purpose of the
present study was to test the feasibility of gadoxetate disodium enhanced 3D T1 MR cholangi-
ography (MRC) with a specific inversion recovery prepulse for the assessment of the hepato-
biliary system, compared to the standard T2 MRCP approach.
Materials and methods
Patients
The study was approved by the institutional review board Institutional Review Board (Charite´
Universita¨tsmedizin Berlin Ethikkommission, Ethikausschuss 1 am Campus Charite—Mitte).
30 patients (12 men, 18 women, 26–79 years, mean 53 years ± 15) underwent gadoxetate diso-
dium enhanced MRI of the liver after written informed consent to participate in the study.
Patients were referred to MRI for evaluation of metastatic disease due to primary cancer of the
breast (n = 7), of the thyroid gland (n = 1), of the gastrointestinal tract (n = 2), melanoma
(n = 1), extragonadal tumor (n = 1), neuroendocrine tumor (n = 3), angiosarcoma (n = 1), and
due to HCC (n = 3). Non-malignant indications (n = 11) were suspected FNH on ultrasound
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and hemochromatosis. Exclusion criteria were age younger than 18 years, pregnancy, metallic
implants or functional devices not eligible for MR examination, claustrophobia, a history of
allergic reaction to Gd-EOB-DTPA, and a glomerular filtration rate below 30 ml/min.
Imaging protocol
MR imaging was performed on a 1.5 T scanner (Avanto, Siemens Medical Solutions, Erlangen,
Germany) equipped with a 32-channel body-phased-array coil. Patients underwent the stan-
dard liver MR imaging protocol using the hepatocyte specific contrast agent gadoxetate diso-
dium which includes an axial T1-weighted spin echo sequence, an axial fat-saturated
T2-weighted turbo spin echo sequence acquired with a 2D navigator for abdominal imaging
(2D Prospective Acquisition Correction, PACE), and an axial T1-weighted dual echo
sequence. A conventional T2 weighted MRCP was acquired before axial T1 VIBE (volume-
interpolated breath-hold) sequences for dynamic imaging before and 15, 55 seconds and 2, 5,
10 and 20 minutes after contrast agent administration and a coronally orientated T1 VIBE
sequence for the hepatobiliary phase at least 20 minutes after contrast agent administration.
In addition, a navigator-triggered 3D MRC was performed in the paracoronal plane. Imag-
ing parameters for T2 MRCP and T1 3D MRC are given in Table 1.
Image analysis
All imaging sequences including the study sequence were analyzed on standard workstations
(Centricity PACS, Radiology RA1000, General Electrics).
Qualitative evaluation. Biliary duct depiction quality was assessed following a 5-point
Likert scale (5: excellent– 4: good– 3: moderate– 2: poor– 1: not visible at all) separately for the
following segments: common bile duct (CBD), common hepatic duct (CHD), cystic duct, right
and left hepatic duct, first, second, and third order branches.
Impairment of biliary tract assessment by bowel movement was recorded likewise using a
5-point Likert scale with 5 meaning no impairment at all, 4 indicating discrete impairment, 3
indicating moderate impairment, 2 indicating prominent impairment, and 1 meaning cholan-
giography not diagnostic due to very intense impairment by bowel movement.
Relative position of the central extrahepatic bile ducts to other hilar structures, namely the
portal vein and to the duodenum was rated on a 3-point Likert scale (2 –good; 1 –moderate; 0
–other structures not visible at all).
Finally, all-over image quality was rated on a 5-point Likert scale (5 –excellent; 4 –good; 3 –
moderate; 2 –poor; 1 –non diagnostic).
Table 1. Imaging parameters of the institutional standard T2 MRCP protocol and T1 3D MRC parameters.
Sequence
parameters
T2 MRCP T1 3D MRC
TR (ms) 1600 377.70
TE (ms) 622 1.79
FoV read (mm) 380 380
FoV phase (%) 100 100
Slice thickness (mm) 1.5 1.5
Base resolution 384 384
Phase resolution (%) 100 100
MRCP magnetic resonance cholangiopancreaticography MRC magnetic resonance cholangiography TR repetition
time TE echo time FoV field of view
https://doi.org/10.1371/journal.pone.0203476.t001
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Quantitative evaluation
For quantitative evaluation of the biliary tract depiction, a circular region-of-interest (ROI)
was placed within the common bile duct, the common hepatic duct (CHD) and the cystic
duct. The size of the ROI was chosen as large as possible, carefully avoiding extrabiliary space.
Signal-to-noise ratio (SNR) was calculated dividing signal intensity of the biliary segment by
extracorporal signal intensity.
Statistical analysis
Mean, range and standard deviation were calculated for presentation of the values of SNR as
well as for qualitative parameters. Metric T1 3D MRC and T2 MRCP data sets were compared
using a student’s unpaired t-Test, with a two-tailed distribution for samples of unequal vari-
ance. Ordinal data were compared using the Wilcoxon signed-rank test. A p-value of less than
0.05 was considered statistically significant.
Results
Qualitative evaluation
Biliary duct depiction showed a high image quality with T2 MRCP than navigator-triggered
T1 3D MRC in all segments (see Table 2 and Fig 1).
On navigator-triggered T1 3D MRC, the relative position of the extrahepatic bile ducts
compared to the portal vein was robustly depicted (mean 1.8), whereas on T2 MRCP the portal
vein was not visualised. Relative position to the duodenum was improved on navigator-trig-
gered T1 3D MRC compared to T2 MRCP even though the effect was not significant (1.7 vs.
1.2, p = 0.114) (see Fig 2).
All-over image quality was comparable for both sequences (3.7 vs. 3.5, p = 0.240).
Image examples are given on Figs 3 and 4.
Quantitative evaluation
Signal-to-noise-ratio was lower, yet comparable on navigator-triggered T1 3D MRC compared
to T2 MRCP (see Table 3 and Fig 5).
Table 2. Subjective evaluation of biliary duct depiction.
T1 3D MRC T2 MRCP p
Common bile duct 4.1 4.3 0.345
common hepatic duct 4.3 4.5 1.000
cystic duct 3.5 3.8 0.323
Right hepatic duct 3.5 4.1 0.003
Right first order branch 2.7 3.7 0.001
Right second order branch 1.7 2.9 0.001
Right third order branch 1.3 2.1 0.001
Left hepatic duct 3.5 4.0 0.006
Left first order branch 2.1 3.1 0.000
Left second order branch 1.4 2.0 0.016
Left third order branch 1.2 1.7 0.018
Impairment of biliary tract assessment by bowel movement was lower with navigator-triggered T1 3D MRC than
with T2 MRCP (4.1 vs. 3.2).
https://doi.org/10.1371/journal.pone.0203476.t002
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Discussion
This preliminary study demonstrated that T1 3D MRC of a specific inversion recovery pre-
pulse has potential to complement T2 MRCP in the diagnostic work-up of the biliary system
in patients receiving gadoxetate disodium. Especially for the evaluation of liver structures close
to the hilus the T1 3D MRCP showed advantages compared to the T2 MRCP. This was a result
of the different acquisition technique of the T1 3D MRC, which is not affected by bowel move-
ment, the relative position of the extrahepatic bile ducts compared to the portal vein and the
duodenum.
Standard MRC protocols rely on T2-weighted (T2w) sequences [12, 13]. In the past years,
numerous other techniques, including contrast-enhanced sequences have been evaluated, nev-
ertheless, until now, 3D T2 weighted sequences have proven to provide the visualisation of the
bile ducts of the highest image quality [10, 11, 14]. This is in line with the findings of our
study, as the depiction of the extrahepatic and intrahepatic bile ducts by navigator-triggered
T1 3D MRC can be performed with a high image quality, however not superior to T2 MRCP.
Especially depiction of the intrahepatic branches was inferior to T2 MRCP, which could be a
Fig 1. Subjective depiction of intra- and extrahepatic bile ducts on T2 MRCP and T1 3D MRC. For all segments, depiction on T2 MRCP is of higher quality.
https://doi.org/10.1371/journal.pone.0203476.g001
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result of the relatively low concentration of gadoxetate disodium excreted into the small biliary
tracts.
Nevertheless, the long acquisition time of the T2 MRCP, due to a long echo time, may lead
to deterioration of image quality by bowel movement. In this context different studies have
investigated the application of an orally applicated contrast medium that suppresses signal
from the intestinal lumen, or butylscopolamin to suppress bowel movement. Especially the
Fig 2. SNR of extrahepatic bile ducts on T2 MRCP and T1 3D MRC. SNR on T2 MRCP is slightly higher in all
segments compared to T1 3D MRC.
https://doi.org/10.1371/journal.pone.0203476.g002
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effect of butylscopolamin is still discussed and no clear guidelines have been established [15,
16]. Both substances lead to additional costs, and side effects as well as a potential of allergic
reactions have to be considered.
To achieve a high image quality using navigator-gated T1 3D MRCP following the adminis-
tration of gadoxetate disodium no additional medication is required. Another aspect in favour
of an additional navigator-triggered T1 3D MRC is that full suppression of the background sig-
nal on T2 MRCP does not allow for a relative depiction of the extrahepatic biliary system in
relation to structures close to the liver hilus hilar structures, which can be important in cases of
external obstruction due to vascular pathologies or neoplasm. In these cases, navigator-trig-
gered T1 3D MRC may give valuable additional information as it allows for a depiction of the
adjacent hilar structures, which enables the visualisation of relative positions. Even visualisa-
tion of the duodenum, which, as a fluid containing organ, was visualised on most of the stud-
ies, was inferior to navigator-triggered T1 3D MRC, as in most of the cases bowel movement
reduced the interpretation of the biliary tract on the T2 MRCP. On navigator-triggered T1 3D
MRC, interference with bowel movement was much less important, as it is a very fast sequence
which highly reduces movement artifacts and bowel content was only depicted by the intra-
luminal excretion of gadoxetate disodium into the intestine which usually does not interfere
with image interpretability.
Fig 3. Image examples of T1 3D MRC complementing T2 MRCP. (a,b) In a 75 year-old female patient, on T2 MRCP
(a), an artefact simulated a possible stenosis of the common bile duct (white arrowhead). With T1 MRC (b), a relevant
stenosis could confidentially be excluded (white arrow). (c, d) In a patient with metastasized breast cancer due to
movement of the bowel conspicuity of the central bilary structures was reduced on T2 MRCP Note improved
depiction of the proximal part of the common hepatic duct (white arrow) on T1 3D MRC, which is slightly overlayered
by duodenal filling on T2 MRCP. Additionally, there is a clear delineation of the portal vein on T1 MRC (white
arrowheads).
https://doi.org/10.1371/journal.pone.0203476.g003
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The results of our study are in line with previous studies. So far, other studies also analysed
MRCP data sets using 2D T2 MRCP and contrast-enhanced T1 MRCP [10, 11]. They also
found that T2 MRCP enables the visualisation of the hepatobiliary system of a higher image
quality compared to T1 MRCP. The key difference between these previous studies in our stud-
ies is that we used a specific inversion recovery prepulse to optimise the contrast between the
liver and the hepatobiliary system.
Coherent with other studies, navigator-triggered T1 3D MRC is not superior to conven-
tional T2 MRCP in biliary visualisation for biliary evaluation. However, a combination of T2
MRCP and navigator-triggered T1 3D MRC provides significantly better visualisation of bili-
ary structures than T2 MRCP alone [17].
Fig 4. Maximum intensity projection images of the biliary system (a, c: T2 MRCP, b, d: T1 MRC). 53 year-old
female patient examined due to suspected focal nodular hyperplasia (black arrowhead in T1 MRC, not visible on T2
MRCP). As contrast in T1 MRC is given by gadoxetate disodium, the pancreatic duct visualized on T2 MRCP (white
arrow) is not visualized T1 MRC. Please also note improved conspicuity of the intrahepatic bile ducts on T2 MRCP
compared to T1 MRC, which can also be seen on in a 30 year-old female patient (c, d) who was examined due to
suspected intrahepatic choledocholithiasis (white arrowheads) which could be verified with MR.
https://doi.org/10.1371/journal.pone.0203476.g004
Table 3. Signal-to-noise-ratio of the central bile ducts on T2 MRCP and T1 3D MRC.
T1 3D MRC T2 MRCP p
common bile duct 29.4 33.6 0.464
common hepatic duct 27.8 36.3 0.137
cystic duct 23.6 27.4 0.446
https://doi.org/10.1371/journal.pone.0203476.t003
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Limitations
The main limitation is that in none of the patients external hilar compression of the bile ducts
was present which might have supported the assumption of navigator-triggered T1 3D MRC
being a valuable adjunct to T2 MRCP.
Fig 5. Visualisation of the hilar structures on T2 MRCP and T1 3D MRC. Depiction of the duodenum and thereby
relationship of the biliary structures is better with T1 3D MRC. Additionally, the portal vein is confidentially depicted
which is not visualised at all on T2 MRCP.
https://doi.org/10.1371/journal.pone.0203476.g005
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Conclusion
This preliminary study demonstrated that T1 3D MRC of a specific inversion recovery pre-
pulse has potential to complement T2 MRCP, especially for the evaluation of liver structures
close to the hilus in the diagnostic work-up of the biliary system in patients receiving gadoxe-
tate disodium.
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